NCT00862706

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

An Open-label, Single-arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naïve Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 16 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy of telbivudine in Blacks/African Americans and Hispanics/Latinos with compensated chronic hepatitis B during 52 weeks of treatment

Conditions

• Compensated Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	Telbivudine/LDT600A	Oral once daily

Timeline

• Start date: 2009-04-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2009-03-17
• Last updated: 2016-09-23

Locations

6 sites across 2 countries: United States, Puerto Rico